Glycologix

Beverly, United States Founded: 2016 • Age: 10 yrs
Biopolymers are developed for soft tissue protection and repair.

About Glycologix

Glycologix is a company based in Beverly (United States) founded in 2016 by Thomas H Jozefiak.. Glycologix has raised $4.05 million across 5 funding rounds from investors including HHS. The company has 7 employees as of December 31, 2022. Glycologix offers products and services including GLX-100 and Biopolymer Platform. Glycologix operates in a competitive market with competitors including Amphora Medical, EMKinetics, Cogentix Medical, EBT Medical and Valencia Technologies, among others.

  • Headquarter Beverly, United States
  • Employees 7 as on 31 Dec, 2022
  • Founders Thomas H Jozefiak
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Glycologix, Inc.
Operational Areas
Healthcare → Medical Devices & Diagnostics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $4.05 M (USD)

    in 5 rounds

  • Latest Funding Round
  • Investors
  • Employee Count
    7

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Glycologix

Glycologix offers a comprehensive portfolio of products and services, including GLX-100 and Biopolymer Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Targets interstitial cystitis for soft tissue protection and repair.

Provides technology for multiple unmet medical needs in tissue repair.

People of Glycologix
Headcount 1-10
Employee Profiles 3
Employee Profiles
People
Dan Deardorf
CEO
People
Rich Heidebracht
VP, Research & Development
People
Eugene Skrabut
Scientific Consultant

Unlock access to complete

Funding Insights of Glycologix

Glycologix has successfully raised a total of $4.05M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round
  • First Round

    (01 Jun 2018)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2025 Amount Seed - Glycologix Valuation

investors

Dec, 2025 Amount Debt – Conventional - Glycologix Valuation

investors

Apr, 2024 Amount Seed - Glycologix Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Glycologix

Glycologix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Glycologix

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Glycologix

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Glycologix Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Glycologix

Glycologix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amphora Medical, EMKinetics, Cogentix Medical, EBT Medical and Valencia Technologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Radiofrequency ablation device for overactive bladder treatment
domain founded_year HQ Location
Transdermal stimulation therapy is provided for urinary incontinence treatment.
domain founded_year HQ Location
Minimally invasive treatment of voiding dysfunctions and endoscopy solution
domain founded_year HQ Location
Non-invasive neurostimulation devices for overactive bladder are developed.
domain founded_year HQ Location
A coin-sized neuromodulation device for hypertension treatment is developed.
domain founded_year HQ Location
Neurostimulation devices for overactive bladder treatment are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Glycologix

Frequently Asked Questions about Glycologix

When was Glycologix founded?

Glycologix was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Glycologix located?

Glycologix is headquartered in Beverly, United States. It is registered at Beverly, Massachusetts, United States.

Who is the current CEO of Glycologix?

Dan Deardorf is the current CEO of Glycologix.

Is Glycologix a funded company?

Glycologix is a funded company, having raised a total of $4.05M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Jun 01, 2018.

How many employees does Glycologix have?

As of Dec 31, 2022, the latest employee count at Glycologix is 7.

What does Glycologix do?

Glycologix was founded in 2016 and is based in Beverly, United States. Operations center on the development of a non-systemic, highly cross-linked chondroitin sulfate-based biopolymer platform within the biotechnology sector. This platform addresses soft tissue protection and repair for conditions such as interstitial cystitis, dry eye, surgical adhesion prevention, osteoarthritis, disk disease, and wound repair.

Who are the top competitors of Glycologix?

Glycologix's top competitors include Valencia Technologies, Amphora Medical and EMKinetics.

What products or services does Glycologix offer?

Glycologix offers GLX-100 and Biopolymer Platform.

Who are Glycologix's investors?

Glycologix has 1 investor. Key investors include HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available